PRMT5 and ovarian cancer: PRMT5 inhibition has recently been shown to enhance the sensitivity of breast and ovarian cancers to PARP inhibitors [72], and the convergence of alterations in DNA replication and repair genes observed in our data suggests that similar combinations could be effective against poor prognosis neuroblastoma.